- Unaudited FY21 revenue of $25.6M – $25.9M, a 38% – 39% increase on the prior corresponding period (pcp)
- Positive net operating cash flow of $1.6M for Q4, resulting in a full year FY21 positive operating cashflow of $1.1M
- New and renewed contracts with a TCV of $7.3M in Q4, up 52% on Q3 and 97% on pcp
- Opening balance of contracted revenue to be recognised in the new financial year (FY22) of $15.1M, 18% higher than at the same time last year
- Acquired ExtraMed in April 2021, a leading UK provider of patient flow software, expanding Alcidion’s UK market presence whilst providing additional cross-sell opportunities
- Selected as preferred provider (as part of a Consortium) for a major project to provide a consolidated healthcare record and support clinical decision making (via Miya Precision) across the Australian Defence Force with potential Total Contact Value (TCV) for Alcidion of approximately $21M over 5.5 years subject to contract finalisation in Q2 FY22
- Cash balance at 30 June 2021 of $25.0M (PY: $15.9M)
Alcidion Group Limited (‘Alcidion’ or the ‘Company’) today released its Appendix 4C for the quarter ended 30 June 2021 (Q4 FY21) and this business update.
Alcidion Managing Director Kate Quirke said, “Alcidion has delivered a strong final quarter to close an exceptional year of growth. FY21 revenue is expected to be in the range of $25.6M-$25.9M, a record result for the company despite being generated in challenging circumstances under the backdrop of COVID-19, particularly in the UK. Pleasingly, we delivered positive operating cashflow in Q4 and for the full year, highlighting the shift into a sales acceleration phase. ExtraMed contributed $600k to this revenue, being 2.5 months’ worth of activity”.
“We have been able to increase market share across all our core geographies, signing important new and renewed contracts that provide a solid foundation heading into the new financial year. It was particularly pleasing to extend the contract with Western Health for the provision of Miya and to sign contracts to continue to provide integration services to NSW Health. Contract renewals signify customer satisfaction and the positive relationship the company has with its customers.”
“As part of the strategy to accelerate growth and capture the growing UK market opportunities, Alcidion completed the strategic acquisition of ExtraMed, strengthening our patient flow capability and improving our access to 27 NHS trusts (~19% of NHS acute trusts). We have moved quickly to integrate the ExtraMed offering and identify opportunities for Alcidion’s product suite to be deployed.”
“As announced in April, Alcidion (as part of a Consortium) was selected, subject to contract finalisation later this year, as the preferred provider for a major healthcare IT project with the Department of Defence. Whilst this is potentially a major contract financially, more important is the validation it provides our technology as a modular and interoperable solution within major healthcare IT infrastructure projects.”
Based on current unaudited results, Alcidion is expected to report audited FY21 revenue in the range of $25.6M – $25.9M including 2.5 months of ExtraMed revenue. This is a record full year result for the Company, and a 38% – 39% increase on FY20 revenue of $18.6m.
Following a strong H1 with revenue of $11.1M, the Company continued to build on the momentum through H2, delivering revenue of $14.5M – $14.8M. This represents a 39% – 42% increase on the prior corresponding six months (FY20 H2: $10.4M).
During Q4 FY21, Alcidion signed new contracts and renewals with a total contract value of $7.3M, part of which is recognised in FY21, with the majority of the balance to be recognised in FY22.
Alcidion begins FY22 with $15.1M of contracted revenue to be recognised in the coming year, 18% higher than at the same time last year. The Company has a further $2.9m of scheduled renewal revenue (existing customers renewing current subscriptions and licence periods) which is expected to be converted to contracted revenue over FY22.
Contracted revenue for the new financial year only includes revenue (both recurring and non-recurring) from current signed contracts. It does not include the revenue from contracts that will renew during the next twelve months. Contracted revenue builds over the year as existing recurring revenue contracts are renewed and new contracts (for both recurring and non-recurring revenues) are signed.
$10.9M of the $15.1M contracted FY22 revenue at the start of FY22, is recurring revenue. Alcidion defines recurring revenue as contracted subscription fees, product licence fees, annual support and maintenance and other multi-year service contracts.
Cash receipts from customers in Q4 were $9.7M, a 27% increase on pcp. The Company generated positive operating cashflow of $1.6M in Q4, resulting in a full year positive operating cash flow of $1.1M. It should be noted that Alcidion typically experiences a level of seasonality in the cash flows with Q3 and Q4 historically being the strongest cash collection months.
As noted in Item 6 of the Company’s Appendix 4C, payments made to related parties and their associates totalled $272K for the quarter. The payments relate to Directors’ remuneration.
In April, Alcidion announced it had been selected, as part of a Consortium, as the preferred provider for an enterprise Healthcare Knowledge Management (HKM) System for the Department of Defence of the Australian Government.
Alcidion will provide the Longitudinal Health Record component of the HKM via its Miya Precision product, aggregating the data from Consortium partners and other systems across the Defence Force environment. This project further highlights Alcidion’s ability to interoperate with other solutions to unlock and manage data to benefit clinicians and improve healthcare outcomes. It also provides strong validation of Miya Precision’s scalability, as a platform for supporting large-scale healthcare information management across widely dispersed multi-disciplinary healthcare settings.
The initial total contract value to Alcidion of this opportunity is expected to be $21M over an initial 5.5 year term.
The contract is still subject to final negotiations and Commonwealth Government funding approvals which are expected to be concluded in Q4 calendar year 2021, with the project commencing promptly thereafter. The financial value of this contract is therefore not included within any of the contracted revenue figures reported in this Business Update.
Acquisition of ExtraMed
Alcidion acquired ExtraMed in April, a leading UK provider of patient flow management software, adding six new NHS Trusts and increasing the total NHS Trusts with an Alcidion product implemented to 27 or approximately 19% of the NHS acute market.
Additionally, ExtraMed, in partnership with Hitachi Consulting (as the lead contractor), has signed a large-scale healthcare IT contract to build the UK’s first fully integrated hospital-wide Digital Command Centre for initial deployment at Salford Royal Hospital which is part of Northern Care Alliance NHS Group which includes four acute hospitals across two NHS trusts. The partnership will also provide opportunities for Alcidion to position Miya Precision within the emerging Digital Command Centre offering.
During the quarter Alcidion added several significant contract renewals. The company signed a contract extension with eHealth NSW for continued provision of services to support and maintain their Enterprise Services Bus (ESB). During the quarter, this contract was not only renewed but the scope of the services extended to cover additional deliverables. Alcidion also renewed for a further year, plus another optional year, the contract to supply Miya to Western Health in Victoria. Western Health is one of Alcidion’s longest standing Miya customers.
Appointment of CFO
Alcidion expanded its management team during the quarter with the appointment of Matthew Gepp as Chief Financial Officer, effective as of 7 June. Mr Gepp joins with 17 years’ experience holding senior finance and leadership positions, including most recently as the CFO of ASX listed technology and software company, MNF Group and 10 years prior international experience in financial roles in London and Europe.
At the end of the quarter, Alcidion co-founder and Non-Executive Director Raymond Blight stepped down from the board in alignment with his consulting agreement which concluded on 30 June 2021 and as part of a board-led renewal and succession planning process.
The Company is well advanced in appointing a replacement Non-Executive Director, with a strong pool of candidates highly engaged and enthused at the prospect of joining the Alcidion Board at this time of significant momentum and strong growth prospects.
Alcidion Managing Director Kate Quirke will host an audio webcast with investors via Zoom this morning at 9:00am Australian Eastern Standard Time (AEST).
To register for the webcast, please follow this link: https://us02web.zoom.us/webinar/register/WN_OtpNxtLATI2X77NnClzYZA
Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-in details.